VP, R&D, Molecular Assay Development

Leads the Global Assay Development organization (US/EU) within Bio-Rad's Clinical Diagnostics Group, setting multi- modality portfolio strategy and translating it into robust, scalable IVD assays—with particular depth in molecular (PCR, real-time PCR, digital PCR, and sequencing-based) diagnostics. Owns assay development governance (phase-gate, metrics, and risk reviews) at the portfolio level and is the final escalation point for technical, quality, regulatory, and supply constraints that cross platform or functional lines.

Owns the organization's operating plan, budget, and talent strategy, directly managing and developing Sr. Directors, and represents Global Assay Development to Quality/Regulatory and executive leadership on design control strategy supporting FDA/IVDR/CE submissions and audits.

• Set the strategic direction and multi-year investment strategy for the Global Assay Development organization across all assay modalities — with particular depth in molecular (PCR, real-time PCR, digital PCR, and sequencing-based) diagnostics — partnering with Business Unit leaders, Marketing, and Finance to commit R&D investment against growth, margin, and menu-expansion targets.
• Own the phase-gate governance framework, org-wide development standards, and analytical/clinical performance bar across all assay modalities, setting the go/no-go criteria and quality thresholds that Sr. Directors and Directors execute against.
• Serve as the R&D executive sponsor for design-control governance, representing Global Assay Development to Quality/Regulatory leadership and to FDA/IVDR/CE auditors and inspectors on major submissions and inspections.
• Set the multi-year technology strategy for emerging assay science across all modalities, deciding where the organization builds proprietary capability versus partners, licenses, or acquires — approving major make/buy/partner and licensing decisions and leading executive-level technical due diligence with Legal/Corporate Development.
• Own the organization's operating plan, budget, and talent strategy; build and scale world-class technical leadership across all modalities, and personally engage on the highest-risk, highest-visibility technical and clinical-readiness decisions that carry portfolio-wide or company-level risk.
• Hold peer-level accountability with Systems/Instrument R&D, Manufacturing, Supply Chain, Clinical, Quality, Regulatory, and Commercial leadership to align the integrated systems roadmap, resolving conflicts that Sr. Directors cannot resolve at the program level.
• Represent Global Assay Development to the CDG executive team and Bio-Rad leadership, owning the narrative on portfolio health, investment tradeoffs, and risk, and defending resourcing decisions at the executive level.
• Own competitive and scientific intelligence for the assay portfolio, translating industry, scientific, and IVD-market trends into executive-level recommendations on where to invest, divest, or accelerate.
• Set relative investment priority and resource allocation across assay modalities (molecular, immunoassay, clinical chemistry, and other platforms) within the Global Assay Development portfolio, balancing growth, margin, and menu expansion goals org-wide.

• Education:
  
  Master’s degree or Ph.D. in Chemistry, Biochemistry, Molecular Biology, Bioengineering, or a related discipline (required).
• Work Experience:
  
  12+ years of progressive leadership in IVD/diagnostics R&D, including significant experience leading assay/reagent development organizations, with particular depth in molecular (PCR, digital PCR, isothermal, or sequencing-based) platforms (required).
• Demonstrated track record delivering molecular assays (PCR-based, digital PCR, or…